NanoViricides Cites NV-387 for 35% Fatal Hantavirus After Cruise Ship Outbreak
NanoViricides underscored that its NV-387 antiviral, which completed Phase I safety trials, could address the Andes hantavirus outbreak on the MV Hondius cruise ship, which resulted in three deaths and one positive case among returning U.S. passengers. The company said NV-387’s broad-spectrum efficacy covers coronaviruses, influenza, RSV, monkeypox and measles.
1. Cruise Ship Hantavirus Outbreak
The MV Hondius cruise ship docked in Tenerife on May 10 after an Andes hantavirus infection onboard led to three fatalities, including the initial patient zero and two others. Eighteen U.S. passengers returned under strict quarantine protocols, with one confirmed positive and another symptomatic individual sent to Nebraska for isolation.
2. NV-387 Broad-Spectrum Antiviral Profile
NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated efficacy against a range of pathogens in animal models, including coronaviruses, RSV, influenza, monkeypox and measles. The company asserts that NV-387’s mechanism could block person-to-person transmission and treat lethal lung infections.
3. Strategic Implications for NanoViricides
The recent outbreak underscores demand for a universal antiviral response capable of rapid deployment and minimal spread containment costs. NanoViricides is positioning NV-387 as the only clinical-stage, broad-spectrum antiviral candidate designed to address over 90% of known and emerging viral threats.